



transpara®

By ScreenPoint Medical

“Je ne veux plus travailler sans Transpara®” Dr Hajer Jerraya, Associate Radiologist, Artois Radiologie, Arras, France



French company Incepto has a long and distinguished reputation in the field of Artificial Intelligence in medicine, so it is no surprise that they have entered into a partnership with ScreenPoint Medical to distribute and support Transpara smart AI for breast cancer detection in France.

“It is an honour for Incepto to work with the ScreenPoint Medical team. They bring a unique expertise in the field of artificial intelligence and breast imaging. Today, the French market is expecting this kind of high-performing solution to support the continuous growth of mammography exams demand. With its outstanding user experience, we are convinced that Transpara technology will be a one-of-a-kind support for doctors in the coming years,” explains Antoine Jomier, CEO of Incepto.

In France over 4.4 million mammography exams are performed every year, with more than 50,000 breast cancers diagnosed. Transpara has the potential to significantly improve the quality and the efficacy of breast screening programmes. The distribution agreement with Incepto includes the full suite of Transpara AI solutions which have been clinically proven in peer reviewed publications to improve mammography reading performance and to achieve a breast cancer detection level equivalent to

Radiologists Transpara was installed at Artois Radiologie in August 2019. So far they've been using it on results from a Hologic Dimensions system, reading on a Medecom workstation. The facility performs over 9500 mammography exams every year, with 60% committed to screening.

One of the team of radiologists is Dr Hajer Jerraya, who comments on Transpara from a clinician's perspective. “I want to improve my diagnostic performance. In other words, to detect cancers with poor prognosis (that have often a benign mammographic appearance) at a very early stage while not over-diagnosing lesions that are not prognostically relevant. In this regard, Transpara alerts me by increasing the degree of perceived suspicion on certain images that may appear benign. There are other benefits. In France we have a national screening program, a first reader performs the mammogram, and further diagnostic workup (additional views if necessary, breast ultrasound for dense breast) at the same session, then normal mammograms are reviewed by a second reader in screening centres. Transpara enhances productivity, especially by helping detecting micro-calcifications for which the algorithm is very good. The tool can reduce the recall rate in the screening phase by marking some features that didn't seem suspicious to the first reader, recalled by the second reader for spot compression view. An alert provided by AI guides the second reading and may therefore avoid patient recall after this reading.

In summary, Transpara is very good at detection and increases my diagnostic confidence, offering me a safety net, especially at the end of the day.

SPM-SMR-001-035-1.0

© 2020 ScreenPoint Medical BV. Transpara® is a registered trademark of ScreenPoint Medical BV. Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of ScreenPoint Medical. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because ScreenPoint Medical materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products and features are available in a particular country, please contact your local representative or write to info@screenpointmed.com

Toernooiveld 300, 6525 EC, Nijmegen, The Netherlands // Tel.: +31 24 202 00 20 // info@screenpointmed.com

SCREENPOINT
Medical